NIH:OVCAR-3 [OVCAR3] (ATCC® HTB-161)

Organism: Homo sapiens, human  /  Cell Type: epithelial  /  Tissue: ovary  /  Disease: adenocarcinoma

Permits and Restrictions

View Permits

Organism Homo sapiens, human
Tissue ovary
Cell Type epithelial
Product Format frozen
Morphology epithelial
Culture Properties adherent
Biosafety Level 1
Disease adenocarcinoma
Age 60 years
Gender female
Ethnicity Caucasian
Applications
This cell line is a suitable transfection host.

NIH:OVCAR-3 is an appropriate model system in which to study drug resistance in ovarian cancer, and the presence of hormone receptors should be useful for the evaluation of hormonal therapy.
Storage Conditions liquid nitrogen vapor temperature
Karyotype The cell line is aneuploid human female, with chromosome counts in the sub to near-triploid range. Several normal chromosomes (N11, N13, N14, N15, N16, N17, and N22) are clearly under-represented. Many of these missing chromosomes are represented in the large number of cytogenetically altered chromosomes identified as marker chromosomes. In addition to the marker chromosomes, there are a large number of other structurally abnormal and unassignable chromosomes that are not recognized as markers. Random loss and gain of chromosomes from cell to cell are noted in the exact chromosome counts and in the analysis of the karyotypes.
Images
Derivation
The NIH:OVCAR-3 line was established in 1982 by T.C. Hamilton, et al. from the malignant ascites of a patient with progressive adenocarcinoma of the ovary.
Clinical Data
Caucasian
female
60 years
Receptor Expression Androgen receptor, positive; estrogen receptor, positive; progesterone receptor, positive
Tumorigenic Yes
Effects
Yes, Forms colonies in soft agar
Yes, in nude mice inoculated subcutaneously with 10(7) cells
Comments
Forms colonies in soft agar and has an abnormal karyotype.
Resistant to clinically relevant concentrations of adriamycin, melphalan and cisplatin.
Both cultured cells and xenografts exhibit androgen and estrogen receptors.
Xenograft models have been used to show that treatment with 17 beta estradiol can induce progesterone receptors in this human ovarian carcinoma.
Complete Growth Medium The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: 0.01 mg/ml bovine insulin; fetal bovine serum to a final concentration of 20%.
Subculturing
Volumes used in this protocol are for 75 sq cm flasks; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes. Corning® T-75 flasks (catalog #430641) are recommended for subculturing this product.

  1. Remove and discard culture medium.
  2. Briefly rinse the cell layer with Ca++/Mg++ free Dulbecco's phosphate-buffered saline (D-PBS) or 0.25% (w/v) Trypsin - 0.53 mM EDTA solution to remove all traces of serum which contains trypsin inhibitor.
  3. Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
    Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
  4. Add 2.0 to 3.0 mL of complete growth medium and aspirate cells by gently pipetting
  5. Resuspend the cell pellet in fresh growth medium. Add appropriate aliquots of the cell suspension to new culture vessels.
  6. Incubate cultures at 37°C.
Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:4 is recommended
Medium Renewal: Every 2 to 3 days
Cryopreservation
Freeze medium: Complete growth medium, 95%; DMSO, 5%
Storage temperature: liquid nitrogen vapor temperature
Culture Conditions
Temperature: 37°C

Atmosphere: air, 95%; carbon dioxide (CO2), 5%
STR Profile
Amelogenin: X
CSF1PO: 11,12
D13S317: 12
D16S539: 12
D5S818: 11,12
D7S820: 10
THO1: 9,9.3
TPOX: 8
vWA: 17
Isoenzymes
AK-1, 1
ES-D, 1
G6PD, B
GLO-I, 1
PGM1, 1
PGM3, 1
Name of Depositor R Ozols, TC Hamilton
Year of Origin 1982
References

Hamilton TC, et al. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res. 43: 5379-5389, 1983. PubMed: 6604576

Hamilton TC, et al. Induction of progesterone receptor with 17beta-estradiol in human ovarian cancer. J. Clin. Endocrinol. Metab. 59: 561-563, 1984. PubMed: 6746867

Rogan AM, et al. Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science 224: 994-996, 1984. PubMed: 6372095

Hamilton TC, et al. Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice. Cancer Res. 44: 5286-5290, 1984. PubMed: 6333272

Green JA, et al. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. Cancer Res. 44: 5427-5431, 1984. PubMed: 6488194

Caffrey PB, Frenkel GD. Selenite cytotoxicity in drug resistant and nonresistant human ovarian tumor cells. Cancer Res. 52: 4812-4816, 1992. PubMed: 1511444

Hamilton TC, et al. Experimental model systems of ovarian cancer: applications to the design and evaluation of new treatment approaches. Semin. Oncol. 11: 285-298, 1984. PubMed: 6385258

Godwin AK, et al. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc. Natl. Acad. Sci. USA 89: 3070-3074, 1992. PubMed: 1348364

Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc. Natl. Acad. Sci. USA 93: 136-140, 1996. PubMed: 8552591

Omelyanenko V, et al. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro. Int. J. Cancer 75: 600-608, 1998. PubMed: 9466663

Tumors developed within 21 days at 100% frequency (5/5).

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Other Documentation
FAQ's
  1. Morphology of ATCC® HTB-161


    Date Updated: 3/27/2014

  2. Propagating ATCC® HTB-161


    Date Updated: 3/27/2014

References

Hamilton TC, et al. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res. 43: 5379-5389, 1983. PubMed: 6604576

Hamilton TC, et al. Induction of progesterone receptor with 17beta-estradiol in human ovarian cancer. J. Clin. Endocrinol. Metab. 59: 561-563, 1984. PubMed: 6746867

Rogan AM, et al. Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science 224: 994-996, 1984. PubMed: 6372095

Hamilton TC, et al. Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice. Cancer Res. 44: 5286-5290, 1984. PubMed: 6333272

Green JA, et al. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. Cancer Res. 44: 5427-5431, 1984. PubMed: 6488194

Caffrey PB, Frenkel GD. Selenite cytotoxicity in drug resistant and nonresistant human ovarian tumor cells. Cancer Res. 52: 4812-4816, 1992. PubMed: 1511444

Hamilton TC, et al. Experimental model systems of ovarian cancer: applications to the design and evaluation of new treatment approaches. Semin. Oncol. 11: 285-298, 1984. PubMed: 6385258

Godwin AK, et al. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc. Natl. Acad. Sci. USA 89: 3070-3074, 1992. PubMed: 1348364

Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc. Natl. Acad. Sci. USA 93: 136-140, 1996. PubMed: 8552591

Omelyanenko V, et al. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro. Int. J. Cancer 75: 600-608, 1998. PubMed: 9466663

Tumors developed within 21 days at 100% frequency (5/5).